Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Technosphere Insulin,Degludec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MannKind Completes Enrollment Goal for INHALE-1 Pediatric Diabetes Trial with Afrezza®
Details : Afrezza (technosphere insulin) is a USFDA approved insulin receptor agonist which is being evaluated for the treatment of type 1 or type 2 diabetes in pediatric patients.
Brand Name : Afrezza
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 15, 2024
Lead Product(s) : Technosphere Insulin,Degludec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?